Daniel Antonio González Padilla, MD

González Padilla is a urologist with the Clínica Universidad de Navarra in Madrid, Spain.

Articles by Daniel Antonio González Padilla, MD

Targeting BCG resistance in high-risk NMIBC

January 23rd 2026

Although BCG has been the standard of care for decades and remains the most effective available treatment, outcomes remain suboptimal for many patients.

CREST and POTOMAC: Redefining immunotherapy’s role in NMIBC

ByDaniel Antonio González Padilla, MD

January 19th 2026

Daniel Antonio González Padilla, MD

Articles by Daniel Antonio González Padilla, MD

Targeting BCG resistance in high-risk NMIBC

CREST and POTOMAC: Redefining immunotherapy’s role in NMIBC

Latest Updated Articles

Trending on Urology Times

The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD

FDA approves sildenafil oral film for men with erectile dysfunction

Pearls & Perspectives: Modern Semen Testing and Male Fertility Care, with Thomas Masterson, MD

Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC

URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues